$83.17-5.2%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 13, 2026
Just reported
From Inhibrx Biosciences, Inc.'s results release of November 13, 2026; its quarterly report has since been filed.
Actual
$2M
Guided
—
No guide given
Actual
-$2.46
Guided
—
No guide given
Actual
-$31.7M
Guided
—
No guide given
| Measure | 3 months toSep 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $2M | $1.3M | +53.85% |
| Profit | -$38.7M | -$35.3M | -9.86% |
| Profit per share | -$2.46 | -$2.28 | -7.89% |
| Free Cash Flow | -$34.6M | -$33.8M | -2.36% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Inhibrx Biosciences, Inc. reported on November 13, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
Inhibrx is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Inhibrx’s current clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and ordastobart (INBRX-106), both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what Inhibrx believes to be the most appropriate agonist function.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Inhibrx Biosciences, Inc.’s Item 2.02 8-K filed November 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.